RT Journal Article
SR Electronic
T1 Time trends in social contacts of individuals according to comorbidity and vaccination status, before and during the COVID-19 pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.02.21267205
DO 10.1101/2021.12.02.21267205
A1 Godbout, Aurélie
A1 Drolet, Mélanie
A1 Mondor, Myrto
A1 Simard, Marc
A1 Sauvageau, Chantal
A1 De Serres, Gaston
A1 Brisson, Marc
YR 2022
UL http://medrxiv.org/content/early/2022/05/06/2021.12.02.21267205.abstract
AB Background As we are confronted with more transmissible/severe variants with immune escape and the waning of vaccine efficacy, it is particularly relevant to understand how the social contacts of individuals at greater risk of COVID-19 complications evolved over time. We described time trends in social contacts of individuals according to comorbidity and vaccination status before and during the first three waves of the COVID-19 pandemic in Quebec, Canada.Methods We used data from CONNECT, a repeated cross-sectional population-based survey of social contacts conducted before (2018/2019) and during the pandemic (April 2020 to July 2021). We recruited non-institutionalized adults from Quebec, Canada, by random digit dialling. We used a self-administered web-based questionnaire to measure the number of social contacts of participants (two-way conversation at a distance ≤2 meters or a physical contact, irrespective of masking). We compared the mean number of contacts/day according to the comorbidity status of participants (pre-existing medical conditions with symptoms/medication in the past 12 months) and 1-dose vaccination status during the third wave. All analyses were performed using weighted generalized linear models with a Poisson distribution and robust variance.Results A total of 1441 and 5185 participants with and without comorbidities, respectively, were included in the analyses. Contacts significantly decreased from a mean of 6.1 (95%CI 4.9–7.3) before the pandemic to 3.2 (95%CI 2.5–3.9) during the first wave among individuals with comorbidities, and from 8.1 (95%CI 7.3–9.0) to 2.7 (95%CI 2.2–3.2) among individuals without comorbidities. Individuals with comorbidities maintained fewer contacts than those without comorbidities in the second wave, with a significant difference before the Christmas 2020/2021 holidays (2.9 (95%CI 2.5–3.2) v 3.9 (95%CI 3.5–4.3); P<0.001). During the third wave, contacts were similar for individuals with (4.1, 95%CI 3.4– 4.7) and without comorbidities (4.5, 95%CI 4.1–4.9; P=0.27). This could be partly explained by individuals with comorbidities vaccinated with their first dose who increased their contacts to the level of those without comorbidities.Conclusions It will be important to closely monitor COVID-19-related outcomes and social contacts by comorbidity and vaccination status to inform targeted or population-based interventions (e.g., booster doses of the vaccine).Competing Interest StatementGDS has received research grants from Pfizer unrelated to the current work, and declares no other relationships or activities that could appear to have influenced the submitted work. All other authors declare that they have no competing interests.Funding StatementCONNECT was funded by the Canadian Immunization Research Network, the Canadian Institutes of Health Research (foundation scheme grant FDN 143283), the Institut National de Santé Publique du Québec, and the Fonds de recherche du Québec Santé research (scholars award to MB). The funders had no role in considering the study design or in the collection, analysis, or interpretation of data, the writing of the report, or the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The CONNECT study was approved by the ethics committee at the Centre de recherche du CHU de Québec-Université Laval (project 2016-2172).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analysed during the current study are not publicly available due to the dataset containing sensitive personal data. Aggregated data are available from the corresponding author upon reasonable request.CIConfidence intervalINSPQInstitut national de santé publique du QuébecNACINational Advisory Committee on ImmunizationSTROBEStrengthening the Reporting of Observational Studies in Epidemiology